Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Valiltramiprosate

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Anokion Presents ANK-700 Data For Multiple Sclerosis
    Anokion Presents ANK-700 Data For Multiple Sclerosis

    18 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240917374019/en

    BUSINESSWIRE
    18 Sep 2024
    Share Share
    Alzheon To Present ALZ-801 Trial Results At Alzheimer's Conference
    Alzheon To Present ALZ-801 Trial Results At Alzheimer's Conference

    23 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240723403529/en

    BUSINESSWIRE
    23 Jul 2024
    Share Share
    Alzheon Raises $100M Series E For Alzheimer's Drug Development
    Alzheon Raises $100M Series E For Alzheimer's Drug Development

    12 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240612246496/en

    BUSINESSWIRE
    12 Jun 2024
    Share Share
    Alzheon Doses First Patient In APOLLOE4 Extension, Launches Phase 2
    Alzheon Doses First Patient In APOLLOE4 Extension, Launches Phase 2

    30 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240430939765/en

    BUSINESSWIRE
    30 Apr 2024
    Share Share
    Alzheon’s oral anti-amyloid drug has to be first oral A?-targeting approved
    Alzheon’s oral anti-amyloid drug has to be first oral A?-targeting approved

    18 Apr 2024

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/govt-mulls-allowing-the-sale-of-common-medicines-in-general-stores/articleshow/109394340.cms

    ECONOMICTIMES
    18 Apr 2024
    Share Share
    Alzheon Announces that U.S. Patent Office Invalidating ALZ-801/Valiltramiprosate
    Alzheon Announces that U.S. Patent Office Invalidating ALZ-801/Valiltramiprosate

    08 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240408711851/en

    BUSINESSWIRE
    08 Apr 2024
    Share Share